Cyclin D1 guanine/adenine 870 polymorphism with altered protein expression is associated with genomic instability and aggressive clinical biology of esophageal adenocarcinoma

Julie G. Izzo, Tsung Teh Wu, Xifeng Wu, Joe Ensor, Rajyalakshmi Luthra, Jennifer Pan, Arlene Correa, Stephen G. Swisher, Clifford K S Chao, Walter N. Hittelman, Jaffer A. Ajani

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Purpose: Altered cyclin D1 (CD1), a cell cycle regulator, may play an important role in imparting aggressive nature to esophageal adenocarcinoma (EAC). CD1 gene single nucleotide polymorphism G/A870 results in two alternatively spliced transcripts, CD1a and CD1b. CD1b, preferentially encoded by the A870 allele, is putatively oncogenic. We hypothesized that CD1 A870 allele would be associated with higher CD1 protein expression, and increased genomic instability during EAC evolution, leading to more aggressive phenotype. Patients and Methods: One hundred twenty-four archival specimens of EAC, and 39 associated Barrett's esophagus (BE) specimens were examined for CD1 genotype, CD1 protein expression, and chromosome 9 polysomy (representing genomic instability). We correlated CD1 genotypes with CD1 protein expression, genomic instability, age at diagnosis of EAC, and overall survival (OS). Results: The A870 allele was associated with higher levels of CD1 protein expression in EAC (P = .032); in BE (P = .01) where it was associated with concomitant increased chromosome 9 polysomy (P = .002); and with a younger age at diagnosis (P < .001) and poor OS (P = .0003) of EAC patients. Conclusion: Our data suggest that CD1 A870 background may be imparting aggressive phenotype to EAC. It provides a molecular basis to explain the clinical biology associated with CD1 polymorphism whereas aberrant nuclear accumulation of CD1 protein enhances the acquisition of genomic instability (ie, clonal diversity), thus leading to early age of EAC diagnosis and poor OS. CD1 genotyping with other biomarkers may help create a biomarker-based prognostic model for EAC and CD1 may also serve as a therapeutic target.

Original languageEnglish (US)
Pages (from-to)698-707
Number of pages10
JournalJournal of Clinical Oncology
Volume25
Issue number6
DOIs
StatePublished - Feb 20 2007
Externally publishedYes

Fingerprint

Genomic Instability
Cyclin D1
Guanine
Adenine
Adenocarcinoma
Proteins
Chromosomes, Human, Pair 9
Barrett Esophagus
Alleles
Survival
Biomarkers
Genotype
bcl-1 Genes
Phenotype
Single Nucleotide Polymorphism
Cell Cycle

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Cyclin D1 guanine/adenine 870 polymorphism with altered protein expression is associated with genomic instability and aggressive clinical biology of esophageal adenocarcinoma. / Izzo, Julie G.; Wu, Tsung Teh; Wu, Xifeng; Ensor, Joe; Luthra, Rajyalakshmi; Pan, Jennifer; Correa, Arlene; Swisher, Stephen G.; Chao, Clifford K S; Hittelman, Walter N.; Ajani, Jaffer A.

In: Journal of Clinical Oncology, Vol. 25, No. 6, 20.02.2007, p. 698-707.

Research output: Contribution to journalArticle

Izzo, Julie G. ; Wu, Tsung Teh ; Wu, Xifeng ; Ensor, Joe ; Luthra, Rajyalakshmi ; Pan, Jennifer ; Correa, Arlene ; Swisher, Stephen G. ; Chao, Clifford K S ; Hittelman, Walter N. ; Ajani, Jaffer A. / Cyclin D1 guanine/adenine 870 polymorphism with altered protein expression is associated with genomic instability and aggressive clinical biology of esophageal adenocarcinoma. In: Journal of Clinical Oncology. 2007 ; Vol. 25, No. 6. pp. 698-707.
@article{fdb34905d81446398263995f25541ee6,
title = "Cyclin D1 guanine/adenine 870 polymorphism with altered protein expression is associated with genomic instability and aggressive clinical biology of esophageal adenocarcinoma",
abstract = "Purpose: Altered cyclin D1 (CD1), a cell cycle regulator, may play an important role in imparting aggressive nature to esophageal adenocarcinoma (EAC). CD1 gene single nucleotide polymorphism G/A870 results in two alternatively spliced transcripts, CD1a and CD1b. CD1b, preferentially encoded by the A870 allele, is putatively oncogenic. We hypothesized that CD1 A870 allele would be associated with higher CD1 protein expression, and increased genomic instability during EAC evolution, leading to more aggressive phenotype. Patients and Methods: One hundred twenty-four archival specimens of EAC, and 39 associated Barrett's esophagus (BE) specimens were examined for CD1 genotype, CD1 protein expression, and chromosome 9 polysomy (representing genomic instability). We correlated CD1 genotypes with CD1 protein expression, genomic instability, age at diagnosis of EAC, and overall survival (OS). Results: The A870 allele was associated with higher levels of CD1 protein expression in EAC (P = .032); in BE (P = .01) where it was associated with concomitant increased chromosome 9 polysomy (P = .002); and with a younger age at diagnosis (P < .001) and poor OS (P = .0003) of EAC patients. Conclusion: Our data suggest that CD1 A870 background may be imparting aggressive phenotype to EAC. It provides a molecular basis to explain the clinical biology associated with CD1 polymorphism whereas aberrant nuclear accumulation of CD1 protein enhances the acquisition of genomic instability (ie, clonal diversity), thus leading to early age of EAC diagnosis and poor OS. CD1 genotyping with other biomarkers may help create a biomarker-based prognostic model for EAC and CD1 may also serve as a therapeutic target.",
author = "Izzo, {Julie G.} and Wu, {Tsung Teh} and Xifeng Wu and Joe Ensor and Rajyalakshmi Luthra and Jennifer Pan and Arlene Correa and Swisher, {Stephen G.} and Chao, {Clifford K S} and Hittelman, {Walter N.} and Ajani, {Jaffer A.}",
year = "2007",
month = "2",
day = "20",
doi = "10.1200/JCO.2006.08.0283",
language = "English (US)",
volume = "25",
pages = "698--707",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "6",

}

TY - JOUR

T1 - Cyclin D1 guanine/adenine 870 polymorphism with altered protein expression is associated with genomic instability and aggressive clinical biology of esophageal adenocarcinoma

AU - Izzo, Julie G.

AU - Wu, Tsung Teh

AU - Wu, Xifeng

AU - Ensor, Joe

AU - Luthra, Rajyalakshmi

AU - Pan, Jennifer

AU - Correa, Arlene

AU - Swisher, Stephen G.

AU - Chao, Clifford K S

AU - Hittelman, Walter N.

AU - Ajani, Jaffer A.

PY - 2007/2/20

Y1 - 2007/2/20

N2 - Purpose: Altered cyclin D1 (CD1), a cell cycle regulator, may play an important role in imparting aggressive nature to esophageal adenocarcinoma (EAC). CD1 gene single nucleotide polymorphism G/A870 results in two alternatively spliced transcripts, CD1a and CD1b. CD1b, preferentially encoded by the A870 allele, is putatively oncogenic. We hypothesized that CD1 A870 allele would be associated with higher CD1 protein expression, and increased genomic instability during EAC evolution, leading to more aggressive phenotype. Patients and Methods: One hundred twenty-four archival specimens of EAC, and 39 associated Barrett's esophagus (BE) specimens were examined for CD1 genotype, CD1 protein expression, and chromosome 9 polysomy (representing genomic instability). We correlated CD1 genotypes with CD1 protein expression, genomic instability, age at diagnosis of EAC, and overall survival (OS). Results: The A870 allele was associated with higher levels of CD1 protein expression in EAC (P = .032); in BE (P = .01) where it was associated with concomitant increased chromosome 9 polysomy (P = .002); and with a younger age at diagnosis (P < .001) and poor OS (P = .0003) of EAC patients. Conclusion: Our data suggest that CD1 A870 background may be imparting aggressive phenotype to EAC. It provides a molecular basis to explain the clinical biology associated with CD1 polymorphism whereas aberrant nuclear accumulation of CD1 protein enhances the acquisition of genomic instability (ie, clonal diversity), thus leading to early age of EAC diagnosis and poor OS. CD1 genotyping with other biomarkers may help create a biomarker-based prognostic model for EAC and CD1 may also serve as a therapeutic target.

AB - Purpose: Altered cyclin D1 (CD1), a cell cycle regulator, may play an important role in imparting aggressive nature to esophageal adenocarcinoma (EAC). CD1 gene single nucleotide polymorphism G/A870 results in two alternatively spliced transcripts, CD1a and CD1b. CD1b, preferentially encoded by the A870 allele, is putatively oncogenic. We hypothesized that CD1 A870 allele would be associated with higher CD1 protein expression, and increased genomic instability during EAC evolution, leading to more aggressive phenotype. Patients and Methods: One hundred twenty-four archival specimens of EAC, and 39 associated Barrett's esophagus (BE) specimens were examined for CD1 genotype, CD1 protein expression, and chromosome 9 polysomy (representing genomic instability). We correlated CD1 genotypes with CD1 protein expression, genomic instability, age at diagnosis of EAC, and overall survival (OS). Results: The A870 allele was associated with higher levels of CD1 protein expression in EAC (P = .032); in BE (P = .01) where it was associated with concomitant increased chromosome 9 polysomy (P = .002); and with a younger age at diagnosis (P < .001) and poor OS (P = .0003) of EAC patients. Conclusion: Our data suggest that CD1 A870 background may be imparting aggressive phenotype to EAC. It provides a molecular basis to explain the clinical biology associated with CD1 polymorphism whereas aberrant nuclear accumulation of CD1 protein enhances the acquisition of genomic instability (ie, clonal diversity), thus leading to early age of EAC diagnosis and poor OS. CD1 genotyping with other biomarkers may help create a biomarker-based prognostic model for EAC and CD1 may also serve as a therapeutic target.

UR - http://www.scopus.com/inward/record.url?scp=33947611435&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947611435&partnerID=8YFLogxK

U2 - 10.1200/JCO.2006.08.0283

DO - 10.1200/JCO.2006.08.0283

M3 - Article

C2 - 17308274

AN - SCOPUS:33947611435

VL - 25

SP - 698

EP - 707

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 6

ER -